Alkem Labs Q2 FY26 results: revenue up 17.2%, EBITDA margin at 23.0%

EBITDA margin expansionExceptional itemResults restatedResults View source PDF Explain this filing

ALKEM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-1.2%Reaction day

₹5770.00

prior close

₹5813.00

announcement price

In-mkt

timing

Nifty Midcap 150market · index membership as recorded later (tracked since Jun 2026)-0.3%-0.8% vs market

Pharmaceuticals peers, median of 157sector-0.0%-1.1% vs sector

On the reaction day the stock moved 0.8 pts less than Nifty Midcap 150 and 1.1 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-1.0

10m

-0.8

15m

-0.6

30m

-2.1

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-1.2-0.3-0.8-0.0-1.1

Next day

-0.9-0.3-0.6-0.4-0.4

-0.8+0.4-1.2-0.3-0.4

-1.0-0.2-0.8-1.1+0.1

-0.5+0.1-0.6-1.4+0.9

-1.5+0.1-1.5-1.6+0.1

-2.8-1.4-1.4-3.3+0.5

15d

-2.3-1.2-1.1-3.4+1.1

-2.8-1.2-1.6-4.3+1.5

+1.6-2.1+3.8-6.9+8.5

-6.4-2.3-4.1-8.8+2.3

UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 157Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Alkem Laboratories reported Q2 FY26 consolidated revenue of Rs 40,010 Mn, up 17.2% YoY. EBITDA rose 22.3% to Rs 9,208 Mn with margin expanding to 23.0% from 22.0%. PAT grew 11.1% to Rs 7,651 Mn. India sales up 12.4%, international sales up 29.5%. H1 FY26 revenue Rs 73,721 Mn, up 14.4% YoY. Results include a Rs 142.9 Mn exceptional gain from the sale of the Indore facility. Auditors issued an unmodified review report.

Likely market impact

Strong quarter with broad-based growth across India and international markets. EBITDA margin expansion and double-digit revenue growth signal healthy operating momentum.